{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:15:55Z","timestamp":1777907755998,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>In a clinical trial of 30 patients suffering from psychovegetative disorders and\nanxiety neuroses, Mepiprazol (test designation: EMD 16-923; supplier: E. Merck, Darmstadt,\nFRG) was proven in a treatment period of 14 days to be an effective, well-tolerated\nmedication. Only two patients failed to respond during the course of treatment. Improvements\nwere significant at the 1-percent level between the pretreatment condition and each\ncontrol during the treatment period; even between the rating times there was a significant\nincrement in treatment success. Mepiprazol had a particular effect on symptoms such as\nirritability, anxiety, inner unrest and tension. Mepiprazol also exhibited a positive effect in\nthe treatment of psychosomatic complaints.<\/jats:p>","DOI":"10.1159\/000468162","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:19:51Z","timestamp":1502471991000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Trial of\n3-Methyl-5-(\u03b2-\/V'-[yV-\/M-Chlorophenylpiperazino]Ethyl)-\nPyrazole Dihydrochloride (Mepiprazol) in the Therapy of\nPsychovegetative Disorders"],"prefix":"10.1159","author":[{"given":"W.","family":"P\u00f6ldinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:46:27Z","timestamp":1777643187000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468162","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}